COMPANIES COVERED
Bristol-Myers SquibbDownload FREE Report Sample
Download Free sampleDrugs for Non-Small Cell Lung Cancer Market contains market size and forecasts of Drugs for Non-Small Cell Lung Cancer in Global, including the following market information:
Global Drugs for Non-Small Cell Lung Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Drugs for Non-Small Cell Lung Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Radiofrequency Ablation (RFA) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Drugs for Non-Small Cell Lung Cancer include Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, Ziopharm Oncology, Alchemia, Amgen, Apotex and BioMarin Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Wesurveyed the Drugs for Non-Small Cell Lung Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Non-Small Cell Lung Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Drugs for Non-Small Cell Lung Cancer Market Segment Percentages, by Type, 2021 (%)
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Global Drugs for Non-Small Cell Lung Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Drugs for Non-Small Cell Lung Cancer Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Other
Global Drugs for Non-Small Cell Lung Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Drugs for Non-Small Cell Lung Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Non-Small Cell Lung Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Drugs for Non-Small Cell Lung Cancer revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
